MainStreet Investment Advisors LLC Makes New $1.45 Million Investment in Eli Lilly and Company $LLY

MainStreet Investment Advisors LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent filing with the SEC. The firm purchased 1,895 shares of the company’s stock, valued at approximately $1,446,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Exencial Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after acquiring an additional 11,396 shares in the last quarter. Rede Wealth LLC acquired a new position in shares of Eli Lilly and Company during the third quarter worth about $487,000. Central Pacific Bank Trust Division raised its holdings in shares of Eli Lilly and Company by 25.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock valued at $6,859,000 after buying an additional 1,843 shares during the period. Cidel Asset Management Inc. lifted its position in Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after acquiring an additional 5,591 shares in the last quarter. Finally, Oak Family Advisors LLC purchased a new position in shares of Eli Lilly and Company in the third quarter valued at $1,979,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LLY. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. TD Cowen upped their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Jefferies Financial Group raised their price target on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,228.54.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk said its CagriSema did not meet the primary endpoint of non‑inferiority versus Lilly’s tirzepatide in an 84‑week obesity study, prompting investors to favor Lilly as the dominant player in obesity therapeutics. Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s All Down to This Weight-Loss Drug Trial.
• Positive Sentiment: Confirming coverage: Major outlets and wire services reported the trial miss broadly, accelerating market re‑rating in favor of Lilly’s obesity franchise and reducing short‑term competitive risk. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Positive Sentiment: Analyst upgrades/targets: Wall‑street coverage turned constructive — a published note raised Eli Lilly’s price target (reflecting stronger expected earnings from obesity products) and Erste Group flagged a positive FY2026 earnings outlook for LLY. These help underpin higher valuations. Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,050.00
• Neutral Sentiment: Institutional filing: Empirical Financial Services reported a modest increase in its Eli Lilly holdings in a prior quarter filing — a routine ownership update that adds little immediate directional pressure but signals continued institutional interest. Eli Lilly and Company $LLY Shares Acquired by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,008.47 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market cap of $951.35 billion, a price-to-earnings ratio of 43.94, a price-to-earnings-growth ratio of 1.17 and a beta of 0.39. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The firm has a fifty day moving average of $1,054.83 and a 200-day moving average of $917.84.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 30.15%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.